SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission file number: 001-35223
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On November 17, 2026, BioLineRx Ltd. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with SCOF Motixafortide Holdings, Inc., a Delaware corporation and an affiliate of Soleus Capital Management, L.P. (the “Purchaser”), pursuant to which the Company agreed to sell to the Purchaser a portion of its right to receive future royalty payments on net sales of APHEXDA® (motixafortide) under the Company’s License Agreement with Ayrmid Pharma Ltd. (“Ayrmid”), dated November 20, 2024, as amended (the “Ayrmid License”). The transaction is expected to close on or about November 30, 2026, subject to the satisfaction of customary closing conditions.
Pursuant to the Purchase Agreement, the Company will sell to the Purchaser, at closing, 80% of the royalty payments payable to the Company under the Ayrmid License attributable to sales occurring on or after the closing date, together with related rights, including amounts payable in respect of any underpayment or late payment of such royalties, amounts payable in lieu thereof, and royalties payable under any replacement license entered into following a termination of the Ayrmid License (collectively, the “Purchased Receivables”). As a condition to closing, Ayrmid will consent to the sale and agree to remit the Purchased Receivables directly to the Purchaser. The Company will retain the remaining 20% of such royalty payments. Based on the 18% royalty rate payable to the Company under the Ayrmid License, the 80% interest to be sold to the Purchaser corresponds to a 14.4% royalty on net sales of APHEXDA, and the 20% interest to be retained by the Company corresponds to a 3.6% royalty on net sales, which retained portion is attributable to the royalties the Company is obligated to pay to Biokine Therapeutics Ltd., the original licensor of motixafortide to the Company, under the Company’s upstream license agreement with Biokine.
In consideration for the Purchased Receivables, the Purchaser will pay the Company a one-time purchase price of $5.6 million at closing, less the Purchaser’s documented reasonable transaction expenses capped at $100,000. The Company will retain, among other things, all rights to receive potential future milestone payments under the Ayrmid License.
In addition, Kreos Capital VII Aggregator SCSp (“Kreos”), an affiliate of BlackRock and the lender under the Company’s loan agreement dated September 14, 2022, as amended (the “Loan Agreement”), has consented to the transaction and agreed to release its security interest in the Purchased Receivables. In connection with such consent, the Company and Kreos will enter into a Second Amendment to the Loan Agreement at the closing of the Purchase Agreement (the “Loan Amendment”), pursuant to which the Company will make a partial loan prepayment to Kreos of $3.0 million at such closing. Following such prepayment, the remaining outstanding amount under the Loan Agreement of approximately $2.0 million will be repaid in accordance with a new repayment schedule, the minimum cash balance covenant under the Loan Agreement of $4.0 million will be eliminated, and an amendment to the Company’s floating charge in favor of Kreos will become effective.
The Purchase Agreement contains customary representations, warranties and covenants of the parties for a transaction of this nature, as well as customary closing conditions.
Chardan Capital Markets, LLC acted as financial advisor to the Company in connection with the transaction described herein and will receive a financial advisory fee of approximately $0.4 million, payable upon the closing of the transaction.
The Company intends to use the net proceeds of the transaction, if consummated, to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including the partial repayment of the Loan Agreement described above.
The foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of such document, a copy of which is filed as Exhibit 10.1 to this Report on Form 6-K and is incorporated by reference herein.
On November 18, 2026, the Company issued a press release entitled “BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital.” A copy of the press release is attached hereto as Exhibit 99.1.
This Report on Form 6-K, including all exhibits hereto (other than the press release attached as Exhibit 99.1), is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.
Attached hereto and incorporated by reference herein are the following exhibits:
| Exhibit No. | Description | |
| 10.1(1) | Purchase and Sale Agreement, dated as of November 17, 2026, between BioLineRx Ltd. and SCOF Motixafortide Holdings, Inc. | |
| 99.1 | Press Release dated November 18, 2026 |
(1) Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish a copy of all omitted schedules and exhibits to the SEC upon its request.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioLineRx Ltd. | |||
| By: | /s/ Philip A. Serlin | ||
| Philip A. Serlin | |||
| Chief Executive Officer | |||
Dated: November 18, 2026